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ConcomitantThe study investigated the safety of 4-component meningococcal serogroup B vaccination (4CMenB) in
routine care. 4CMenB exposure and seizures, febrile seizures and Kawasaki disease were identified from
The Health Improvement Network (THIN) database of UK electronic primary healthcare records, 2015–
2018. A self-controlled case series analysis was completed. Anaphylaxis, Guillain-Barré syndrome and
acute disseminated encephalomyelitis were secondary outcomes.
A total of 107,231 children aged 1–18 months received 1 doses of 4CMenB vaccination. Most 4CMenB
exposure (93%) was on the same day as other vaccines within a complete national immunisation program
stage. With day 0 as day of vaccination, 43 seizures occurred in days 0–6 after 239,505 doses, and 23 feb-
rile seizures occurred in days 0–6, and 4 Kawasaki disease cases in days 1–28 after 194,929 4CMenB
doses. Adjusted incidence rate ratios including all 4CMenB exposures were 1.43 (95%CI: 1.02–2.02) for
seizures and 1.72 (95%CI: 1.08–2.75) for febrile seizures. There were insufficient cases to model
Kawasaki disease, and no cases of the secondary outcomes in risk periods when they may be associated
with the vaccination.
This study shows few cases of the outcomes after vaccination including 4CMenB with an increased risk
of seizures and febrile seizures. It is not possible to attribute the finding to one specific vaccination as the
majority of 4CMenB was given with other vaccinations.
Trial registration: NA.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Meningococcal disease is caused by the bacterium Neisseria
meningitidis and is associated with considerable mortality and
morbidity [1] with young children and teenagers at highest risk
of the disease [2]. The 4-component meningococcal serogroup Bvaccine (4CMenB; Bexsero, GSK) was the first multicomponent
meningococcal serogroup B vaccine and was included in the UK
National Immunisation Programme (NIP) from September 2015
(Table 1) for infants born after July 2015 with a catch-up pro-
gramme for children born from 1st May 2015 [2].
Increased rates of fever [3] and cases of febrile seizures [4] after
4CMenB have been reported in some individual clinical trials or
meta-analyses when compared to other vaccinations. Cases of pos-
sible or confirmed Kawasaki disease were reported in the 4CMenB
clinical studies however a relationship with the vaccination could
not be established [5].
The purpose of this study was to assess the safety of 4CMenB
vaccination within UK routine care with regards to three primaryexsero)
Table 1
Age-sex distribution of the descriptive cohort at 4CMenB vaccination, in total and by







1 4CMenB vaccination* 107,231 2.20 (1.84, 2.99);
1.05–18.05
51.3
NIP stage 1: 5-in-1, PCV, rotavirus,
4CMenB (1st dose)
79,038 2.04 (1.78, 2.30);
1.05–14.10
51.1
NIP stage 3: 5-in-1, PCV, 4CMenB
(2nd dose)
83,486 4.14 (3.81, 4.64);
2.04–18.05
51.1
NIP stage booster: Hib, Men C,





Outside a standard NIP stage 17,687 4.44 (3.25, 12.49);
1.05–18.05
51.9
4CMenB, 4-component meningococcal serogroup B vaccine; 5-in-1, diphtheria-
tetanus-pertussis/polio/Haemophilus influenzae type b (and hepatitis B added in
autumn 2017); Hib, Haemophilus influenzae type b; IQR, interquartile range; MenC,
meningitis C; MMR, measles-mumps-rubella; NIP, National Immunisation Pro-
gramme; PCV, 13-valent pneumococcal vaccine.
* Population for the descriptive analysis, age at first 4CMenB vaccination in
observation period. Recommended ages in NIP: Stage 1, 2 months; Stage 3,
4 months; Booster 12–13 months.
ϯ Unique children.
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ondary (acute disseminated encephalomyelitis [ADEM], Guillain-
Barré syndrome [GBS], and anaphylaxis) outcomes.2. Methods
2.1. Data source
The database population comprised 460 practices which con-
tributed data to The Health Improvement Network (THIN) data-
base of primary care electronic healthcare records for all or part
of the study period (1st May 2015 to 31st December 2018 inclu-
sive) (Supplementary table 1). THIN includes demographics, clini-
cal events, prescriptions, and preventive medicine routinely
recorded against date within individual patient records. Secondary
care diagnoses and deaths are captured because of the structure of
the UK National Health Service. Medical events, automatically
coded using the Read coding system [6], can be supplemented with
unstructured text. Vaccination details are recorded in specific
fields. THIN covers approximately 5% of the UK population (2015
figures) and has been shown to be generalizable to the UK popula-
tion although with slightly fewer people aged under 20 years [7].
The study used THIN version IMRD 1809, and IMRD 1801 for the
May 2018 data cut.
THIN has a multicentre ethics approval for observational stud-
ies (Southeast MREC, ref: 03/01/073). This study was approved
by the THIN Scientific Review Board (reference 11THIN028).
2.2. Setting and participants
The study population included children permanently registered
at a practice in the database population when aged between 1 and
18 months on or after 1st May 2015, and who received one or more
vaccination with 4CMenB during an observation period.
An observation period was set to allow appropriate evaluation
of exposure (vaccine administration) and outcome. Observation
for each child started at the most recent of four dates: 1st May
2015, (to include pre-exposure data on children in the catch-up),
date of birth plus one month (as part of the first month of life is
usually spent in secondary care), transfer-in from another practice2
plus three months (prevalent events can be recorded at post-
registration), or data quality assurance dates (based on use of
Vision software and Acceptable Mortality Reporting Dates [8] and
further review). Observation ended at the earliest of four dates:
the month of birth plus 18 months, deregistration (including death
and moving practice), last data collection from the practice, or the
end of the study period for that outcome.
Seizure analyses included the overall study period to 31st
December 2018. All other outcomes used unstructured text in case
identification. This became unavailable under the European Gen-
eral Data Protection Regulation [9] in May 2018. The study period
for outcomes other than seizure was therefore truncated at the last
data cut which included the unstructured text used in case identi-
fication (May 2018). More than one observation period was possi-
ble if a child left and then re-joined the same practice (0.01% of the
study population). When more than one transfer-out date was
recorded for an observation the earliest was used to calculate the
observation period (0.8% of the study population). The self-
controlled case series (SCCS) population for each outcome com-
prised a sub-group of the study population who had that outcome
during their observation.
2.3. Variables
All variables were identified from THIN. 4CMenB vaccination
was defined as a coded entry in the Additional Health Data
(AHD), medical or therapy files. A second 4CMenB vaccination of
the same NIP stage within 28 days was not included (0.1% of
exposures).
Seizures, febrile seizures and Kawasaki disease were primary
outcomes, ADEM, GBS, and anaphylaxis were secondary outcomes.
A seizure was defined as a Read code for seizure or convulsion in
Medical or AHD files during observation (see Supplementary table
2 for all case definitions and Supplementary table 3 for codes). Feb-
rile seizures were a sub-set of seizures defined as a specific code or
evidence of a concomitant fever, without previous diagnosis or
treatment for epilepsy or other relevant concurrent central ner-
vous system disease [10]. Date of onset was the date of the seizure
code. Seizure records within 30 days of a previous record were
treated as the same episode as these were assumed to be follow-
up visits rather than incident events.
Possible Kawasaki disease was identified by specific code in
Medical or AHD files or ‘kawasa’ in unstructured text [11] during
observation plus two months to capture late diagnoses. These epi-
sodes were adjudicated against a case definition and assigned a
date of onset by authors (PP, PH, GH) (Supplementary table 2 for
case definition and date of onset rules) when blinded to exposure
dates. Adjudication was based on the electronic health record
including unstructured text. Additional information was requested
from the practice via a third party and the record re-reviewed if
required. When the initial reviews differed, the case was discussed
until agreement was reached. Episodes of ADEM, GBS, and anaphy-
laxis were identified by code or text and adjudicated using similar
procedures as those for Kawasaki disease. Deaths were reviewed
for a cause that was a study outcome. Date of birth was assumed
to be 16th of the month of birth as THIN includes only the month
for children. Other NIP vaccinations were identified from the AHD
file.
Two validation steps were completed. A questionnaire was sent
to the practices of a random sample of 100 children with a seizure
dated in the first study year and registered at practices which had
agreed to respond to questionnaires. Information was requested on
the date of any seizures and if these were febrile. Positive predic-
tive value (PPV) was computed using the questionnaire as the ‘gold
standard’. The second validation was completed when unstruc-
tured text became unavailable, to understand the effect of losing
G.C. Hall, I. Douglas, P.T. Heath et al. Vaccine xxx (xxxx) xxxunstructured text. The original adjudication of outcomes with
unstructured text to the May 2018 data cut was treated as the gold
standard. The adjudication of the outcomes was repeated without
the unstructured text and the two sets of results compared with
validation indices estimated.
2.4. Study size
THIN comprises patient records from a set number of practices.
Consequently, the study size can only be varied by increasing its
duration. The number of cases and so the number of required study
years required to detect an incidence rate ratio (IRR) of 3 and 10
with 80% power and a 0.05 alpha was estimated from published
background incidence rates and assuming three exposures to
4CMenB per 35,000 newborns per annum (from previous years in
the data source) [12]. The study size for seizures and febrile sei-
zures was estimated as 88 (IRR 3) and 12 (IRR 10) cases which
would be expected to occur within 1 year observation for both out-
comes. For Kawasaki disease sample size and duration was esti-
mated as 32 cases and 6 years (IRR 3) and 7 cases and 1 year
(IRR 10). For secondary outcomes, an SCCS was planned if at least
one episode was identified in the risk period, and the number of
outcomes was that required to detect an IRR of 10 with 80% power.
2.5. Statistical methods
The risk period for each outcome was defined as the number of
days following vaccination during which an outcome would be
expected to occur if causally associated with the vaccine (Fig. 1).
The risk window were assigned based on a review of the literature
during development of the protocol (http://www.encepp.eu/en-
cepp/viewResource.htm?id=33532). A pre-exposure period was
also defined for each outcome as that period of time after an out-
come when a vaccination may be delayed and so a period when
the incidence of outcomes will be low. Baseline time was outside
these two periods and was when the vaccination was assumed to
have no effect on the incidence of the outcome. The incidence rate
of each study outcome was estimated including all episodes of an
outcome in the specific risk period. The incidence pre- and post-
vaccination was plotted. Post-vaccination incidence was plotted
against time intervals between the start of the risk period and
the earliest of the next exposure, 112 days post-exposure or obser-
vation end. Pre-vaccination plots start on the most recent of the
previous exposure, 112 days pre-exposure or observation start,
and end on the day before the risk period. One outcome can there-
fore be depicted in both plots if it is after one exposure but before
subsequent exposures.
In an SCCS analysis IRRs compared the rate of events during
exposed periods of time (risk period) with the rate during other
observed time periods (baseline or control time) [13]. The SCCS
method is derived from the cohort method and relies on intra-
person comparisons in a population of individuals who have both
the outcome and exposure of interest. This method removes the
potential confounding effect of characteristics that vary betweenFig. 1. Illustrative self-controlled c
3
individuals, such as risk factors for disease. Timelines and risk peri-
ods for the SCCS are given in Fig. 1. Day 0 was the day of exposure.
All exposures to 4CMenB were treated as equivalent risk periods.
Conditional Poisson regression was used to calculate IRRs and
95% confidence intervals (95%CIs) comparing the incidence rate
of the outcome in the outcome specific risk period with that during
in the baseline period. Time-varying covariates age (by month),
year of vaccination and respiratory illness season (by quarter) were
included in the model. The pre-exposure period was treated sepa-
rately in the model, as vaccination may be delayed after an out-
come, and so in order to satisfy the SCCS method assumption
that outcomes do not influence the chance of future exposure
(Fig. 1). The primary analysis included the first episode and pri-
mary risk period. If a risk period from one exposure overlapped
with the next pre-exposure period, this time only included the risk
period. If two risk periods overlapped, (for example, if vaccinations
were given within 28 days of each other), the overlapping time was
included in the first risk period only. Time and outcomes for an
exposure before observation were excluded (for example if a child
registered at a practice shortly after vaccination). The SCCS for sei-
zures was repeated by NIP stage. NIP stage was defined as a record
of receiving all vaccinations in the NIP (as of September 2015) [2]
on the same day (Table 1), regardless of age, vaccination history, or
additional vaccinations. Adjustment of the individual NIP stage
model was not stable for febrile seizures (due to low numbers of
outcomes after some NIP stages) so NIP booster, and a combination
of all other exposures in one group was modelled.
Several sensitivity analyses were completed. As per the proto-
col, SCCS models with a longer risk period (seizures), including
observation to 31st December 2018 (febrile seizures and Kawasaki
disease) and including all new episodes rather than first episodes
(febrile seizures) were analysed. A ‘new episode’ was defined as a
gap of 30 or more days since a previous seizure code. Post-hoc sen-
sitivity analyses (further defined after review of results) added NIP
stage 2 to the NIP stage SCCS for seizures and, separately, excluded
exposures with concomitant Hepatitis B vaccine (HepB). HepB was
added to NIP stages 1, 2 and 3 during the study period. The analysis
was completed using SAS Enterprise Guide Version: 7.13 HF3 for
Windows [14].
3. Results
The overall study included 239,505 doses of 4CMenB with
194,929 in the observation period to May 2018 (Fig. 2). The major-
ity of exposures (93%) were on the same day as other vaccinations,
as part of a complete NIP stage (Table 1). There were 816 episodes
of seizures in 695 children, and 399 episodes of febrile seizures in
370 children. Fourteen episodes of anaphylaxis and 9 of Kawasaki
disease of 605 adjudicated events (366 anaphylaxis, 105 Kawasaki
disease, 3 GBS, and 38 ADEM and 93 deaths, 29 agreed after initial
difference) both fulfilled the case definition and were dated within
observation. No second episode of an outcome was identified for
any child. The incidence rate in the primary risk period was 9.4
per 1000 person-years (95%CI 6.8–12.6) for seizures, 6.2 per 1000ase series observation period.
Fig. 2. Identification of the study populations and the number of 4CMenB doses
recorded per child: to 31st December 2018 (May 2018 data cut) *Children may
have had additional 4CMenB vaccinations outside their study observation period.
4CMenB, 4-component meningococcal serogroup B vaccine.
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7.4–69.8) per 100,000 person-years for Kawasaki disease. In sec-
ondary risk periods the incidence rate was 7.3 (95%CI 6.1–8.7)
per 1000 person-years for seizures and 23.0 (95%CI 7.5–53.6) per
100,000 person-years for Kawasaki disease. No GBS or ADEM was
identified during the observation period and no anaphylaxis in
the risk period. The temporal relationship between 4CMenB expo-
sure and first outcomes is shown in Fig. 3.
In the primary SCCS analyses (Table 2) the adjusted IRR and 95%
CI in the risk period for seizures and febrile seizures were above 1
(Table 3). The NIP stage analysis showed similar IRRs for seizures
across stages with 95%CI above 1 only after exposure to the booster
dose of 4CMenB. An increased risk of febrile seizures (95%CI above
1) was observed after the combination of stages except for the
booster stage. Less than 5 episodes of Kawasaki disease in the pri-
mary risk period of 1.6 person-years and five in the baseline period
of 8.0 person years were too few for an adjusted analysis.
In sensitivity analyses, although the second risk period for sei-
zures resulted in a lower IRR the 95% CI remained above 1 and
otherwise the interpretation remained unchanged (Table 4). All
additional cases (<5) of Kawasaki disease in follow-up to the end
of 2018 were in the baseline period. The post-hoc seizure analysis
including NIP stage 2 reported similar IRRs across vaccination
stages although only booster stage confidence intervals were above
1.
The PPV for identification by THIN compared to the practice
questionnaire (91% return) was 80.2% (95%CI 70.2–87.6) for sei-
zures and 84.3% (95%CI 70.9–92.5) for febrile seizures overall. This
indicates that the majority of outcomes identified as seizures were
in fact a seizure. The PPV for five seizures in the risk period was
60.0% (95%CI 17.0% to 92.7%) and 78.3%, (95%CI 67.6% to 86.3%)
for 83 events in the baseline period. As pre-defined, no adjustment
was made for outcome misclassification as there was no significant
difference between groups given the small numbers. Validation
indices for identification of episodes without unstructured text
are given in Supplementary table 4. Episodes of Kawasaki disease
and febrile seizures identified without unstructured text were
identified without false positives (all PPV 100%) in both risk and
baseline periods, however, sensitivity was lower. Anaphylaxis out-
comes were missed when only coded entries were included (sensi-
tivity 35.3%).4. Discussion
This study identified few cases of seizure, febrile seizure, and
Kawasaki disease, and no cases of anaphylaxis, GBS, or ADEM,4
directly after routine vaccination which included 4CMenB. None
of the cases was fatal. The majority of 4CMenB exposure was con-
comitant with other NIP vaccinations. Consequently, it was not
possible to differentiate whether the approximately 1.5 times
increased risk of seizures and febrile seizures was due to one or
other (or the combination) of routine vaccinations.
The strengths of the study are its size (239,505 4CMenB vacci-
nations), comparative design, and observation of events in routine
care. Differential outcome misclassification cannot be ruled out for
seizure outcomes as the confidence intervals surrounding the val-
idation indices against the practice questionnaire were wide. Broad
search criteria followed by adjudication for other outcomes will
have minimised outcome misclassification although a bias may
persist if diagnosis is more likely after exposure to a vaccination.
Most seizures in the study age group are febrile [10]. However,
UK clinicians don’t always classify a seizure as febrile until a child
is a certain age depending on local practice - one, three or six
months. Febrile seizures not classified as such will have been
included in the seizure category. In addition, two risk periods have
been selected for the analysis of seizures; one week to reflect feb-
rile seizures and four weeks to include other seizures. Vaccination
outside the practice will not have impacted the results as the
design does not include unexposed comparators. Despite the study
size, no SCCS analysis was possible for Kawasaki disease and com-
parison between NIP stages for seizure outcomes is limited due to a
lack of statistical power to estimate the IRR with precision. Differ-
entiating between the effects of individual vaccinations in routine
practice with any methodology is difficult given the recommended
schedule.
This is the first investigation of seizures post-vaccination within
current UK routine practice, although an increased risk of febrile
seizures post-vaccination has been reported in other populations.
A much higher risk of febrile seizures (IRR 23, 95%CI 5.13–100.8)
following a median of four concomitant vaccinations (not includ-
ing 4CMenB) was reported in US infants. UK NIP stages in the cur-
rent analysis include up to nine vaccinations, and at least one at
every stage has been associated with a risk of seizures individually
[15–17]. Danish infants had an increased risk of febrile seizures on
the day of the first and second, but not the third diphtheria/teta
nus/pertussis-polio-Haemophilus influenzae type b (DTaP-IPV-Hib)
vaccination, but found no increased risk 0–7 days after any vacci-
nation stage [15]. The incidence of seizures doubled in days 0–59
after dose 1 of the rotavirus vaccine used in the UK [16]. An
increased risk of seizures is also consistent with the effects of the
measles component of measles-mumps-rubella (MMR) vaccination
7–10 days or 6–11 days [18] after exposure which is later than, or
slightly overlapping, the primary risk period in our study. Our post-
hoc analysis including NIP stage 2 (no 4CMenB) may indicate an
increased risk of seizures across all NIP vaccination stages, how-
ever there were too few outcomes to estimate the effect with good
precision. A UK population study reported similar incidences of sei-
zures of 8.3 (95%CI 8.1–8.6) per 1000 person-years aged 2–
12 months (1999–2011) [10]. The slightly higher risk of seizures
when pre-exposure time and outcomes were reassigned into base-
line time would be expected if the events cause a delay in vaccina-
tion (shown by the lower risk in pre-exposure periods), as this
would render a small portion of the baseline time to be immortal
with respect to the outcome and increase the incidence at other
times.
While there were more cases of Kawasaki disease in the shorter
risk period than in the baseline period, a small number of addi-
tional cases identified in the sensitivity analysis to the end of
2018 were in the baseline period demonstrating the risk of inter-
preting results based on small numbers. Kawasaki disease inci-
dences in the current study are aligned (within the wide
confidence intervals) from a study based on the same database
Fig. 3. Incidence of 1st outcomes in relation to 4CMenB exposure * Outcomes can be in both the pre- and post-exposure plot in relation to different exposures. Includes
outcomes 4 months pre- & post-exposure only. Episodes outside this time were not plotted including 3 Kawasaki disease episodes. Seizure and febrile seizures in children
with multiple study periods were excluded. Anaphylaxis horizontal axis is in 2-day intervals with post-exposure starting at day 0. 4CMenB, 4-component meningococcal
serogroup B vaccine; PY, person years.
G.C. Hall, I. Douglas, P.T. Heath et al. Vaccine xxx (xxxx) xxx
5
Table 2





Patients (n) 695 370 9
Male (%) 51.2 54.6 33.3
Mean age at first outcome,
months (SD)
11.2 (4.4) 12.4 (3.3) 6.5 (4.9)
Year of episode n (%)
2015 16 (2.3) NR 0 (0.0)
2016 195 (28.1) 118 (31.9) 5 (55.6)
2017 270 (38.8) 179 (48.4) NR
2018 214 (30.8) 71 (19.2) 0 (0.0)
Season of episode n (%)
Spring 179 (25.8) 98 (26.5) NR
Summer 153 (22.0) 66 (17.8) 5 (55.6)
Autumn 169 (24.3) 79 (21.4) 0 (0.0)
Winter 194 (27.9) 127 (34.3) NR
*Seizures includes data to 31st December 2018, other outcomes to a data cut in May
2018.
SD, standard deviation; NR, not reported as cell contained <5 events.
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Moreover, a recent UK secondary care based study which assessed
the effects of 4CMenB on KD separately to other vaccination expo-
sures reported no increased risk for 4CMenB exposure (relative
incidence 1.03 [95% CI 0.51–2.05] after doses 1 or 2 and 0.64
[95% CI 0.08–5.26] after dose 3) [20].
The clustering of anaphylaxis episodes from approximately
30 days after exposure is consistent with events at the age of first
exposure to solid foods. Previous studies of anaphylaxis have
reported no cases related to ‘routine’ infant and preschool vaccina-
tion in a UK and Ireland study (2008–2009) [21] and post-vaccine
doses [22] in those aged under 18 years. ADEM and GBS are rare
events and the finding of no episodes within the observation per-
iod is consistent with 54 cases of GBS reported in the US in 2004,
[23] and an incidence of ADEM of 0.1–0.2 per 100,000 vaccinated
individuals [24].Table 3
Self-controlled case series primary analysis of all exposures and by complete NIP stage at











SCCS by NIP stage
Seizures*
Baseline period 627
NIP stage 1 8
NIP stage 3 8
NIP booster 22









4CMenB, 4-component meningococcal serogroup B vaccine; CI, confidence interval; N
reported as cell contained <5 events.
* Seizures includes data to 31st December 2018, febrile seizures to a data cut in May
6
Overall, the study demonstrates the safety of 4CMenB after its
inclusion in the UK routine vaccination schedule, with regard to
the study outcomes. This information can be used in conjunction
with effectiveness data to demonstrate the risk-benefit relation-
ship of infant vaccination.
5. Role of the funding source
GlaxoSmithKline Biologicals SA funded this study (GSK study
identifier: 205512). Bexsero is a trademark owned by or licensed
to the GSK group of companies.
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31.6 1.37 (0.99, 1.89) 1.43 (1.02, 2.02)
57.8 0.55 (0.38, 0.81) 0.59 (0.40, 0.86)
380.5 Reference Reference
16.8 1.35 (0.87, 2.10) 1.72 (1.08, 2.75)
30.8 0.28 (0.14, 0.56) 0.36 (0.17, 0.73)
723.5 Reference Reference
9.2 0.94 (0.47, 1.90) 1.50 (0.67, 3.36)
10.3 0.87 (0.43, 1.75) 1.57 (0.74, 3.33)
9.3 2.69 (1.75, 4.14) 1.57 (1.01, 2.46)
NR 0.37 (0.05, 2.65) 0.36 (0.05, 2.62)
57.8 0.55 (0.38, 0.80) 0.59 (0.40, 0.87)
380.5 Reference Reference
11.9 0.55 (0.25, 1.24) 2.62 (1.09, 6.27)
4.9 3.24 (1.91, 5.50) 1.51 (0.88, 2.61)
30.8 0.28 (0.14, 0.56) 0.36 (0.17, 0.73)
IP, National Immunisation Programme; SCCS, self-controlled case series, NR, not
2018. ϯAdjusted for age, season and year.
Table 4
Self-controlled case series sensitivity analyses.
Number of events Person years Crude incidence rate ratio (95%CI) Adjusted incidence rate ratio (95%CI)
All episodes of an outcome rather than 1st episodes
Febrile seizures (day 0–6)
Baseline period 368 378.6 Reference Reference
Risk period 23 16.8 1.36 (0.89, 2.08) 1.83 (1.16, 2.87)
Pre-exposure period 8 0.8 0.25 (0.13, 0.51) 0.34 (0.16, 0.70)
Using risk period 2
Seizures (day 0–27)
Baseline period 543 630.8 Reference Reference
Risk period 123 124.3 1.11 (0.91, 1.36) 1.29 (1.02, 1.64)
Pre-exposure period 29 57.3 0.56 (0.38, 0.81) 0.62 (0.42, 0.93)
Reassigning pre-exposure period and outcomes as baseline
Seizures (day 0–6)
Baseline period 656 781.3 Reference Reference
Risk period 39 31.6 1.42 (1.03, 1.97) 1.55 (1.11, 2.18)
Febrile seizures (day 0–6)
Baseline period 349 411.3 Reference Reference
Risk period 21 16.8 1.44 (0.93, 2.24) 1.91 (1.20, 3.04)
Including data to 31st December 2018
Febrile seizures (day 0–6)
Baseline period 415 486.7 Reference Reference
Risk period 27 21.2 1.47 (1.00, 2.18) 1.82 (1.20, 2.75)
Pre-exposure period 13 38.8 0.39 (0.22, 0.67) 0.48 (0.27, 0.85)
Excluding exposures with concomitant HepB
Seizures (day 0–6)
Baseline period 627 723.5 Reference Reference
Risk period 32 26.4 1.42 (0.99, 2.03) 1.48 (1.02, 2.15)
Pre-exposure period 29 57.8 0.56 (0.38, 0.81) 0.59 (0.40, 0.87)
Febrile seizures (day 0–6)
Baseline period 341 380.5 Reference Reference
Risk period 18 14.9 1.32 (0.82, 2.12) 1.68 (1.02, 2.77)
Pre-exposure period 8 30.8 0.28 (0.14, 0.57) 0.36 (0.17, 0.74)
Including NIP vaccination stage 2
Seizures (day 0–6)
Baseline period 617 697.5 Reference Reference
NIP stage 1 (with 4CMenB) 8 9.2 0.91 (0.45, 1.84) 1.55 (0.68, 3.51)
NIP stage 2 (no 4CMenB) 6 9.8 0.66 (0.29, 1.47) 1.40 (0.58, 3.35)
NIP stage 3 (with 4CMenB) 8 10.3 0.84 (0.42, 1.70) 1.54 (0.73, 3.26)
NIP booster (with 4CMenB) 22 9.3 2.63 (1.71, 4.05) 1.57 (1.01, 2.46)
4CMenB outside NIP stages NR NR 0.36 (0.05, 2.64) 0.36 (0.05, 2.62)
Pre-exposure period 33 74.0 0.48 (0.34, 0.68) 0.58 (0.40, 0.85)
4CMenB, 4-component meningococcal serogroup B vaccine; 95%CI, 95% confidence interval; HepB, hepatitis B vaccination; NIP, National Immunisation Programme, NR, not
reported as cell contained <5 events.
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